Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

Blood
Jean-Luc HarousseauJesus San Miguel

Abstract

The phase 3 Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone study in newly diagnosed multiple myeloma patients ineligible for high-dose therapy demonstrated that bortezomib-melphalan-prednisone (VMP) was superior to melphalan-prednisone across all efficacy end points. We assessed the prognostic impact of response on time-to-event parameters in the intent-to-treat population. Patients received nine 6-week cycles of treatment. Time to progression, time to next therapy, and treatment-free interval were associated with quality of response. When European Group for Blood and Marrow Transplantation criteria were used, complete response (CR) was associated with significantly longer time to progression (hazard ratio [HR] = 0.45, P = .004), time to next therapy (HR = 0.46, P = .0004), and treatment-free interval (HR = 0.38, P < .0001) versus partial response, but there was no significant difference in overall survival (HR = 0.87, P = .54); similar differences were seen with CR versus very good partial response by uniform criteria. Quality of response improved with prolonged VMP treatment, with 28% of CRs achieved during cycles 5-9. CR duration appeared similar among patients with "early" ...Continue Reading

References

Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P CorradiniA Pileri
Jun 28, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·M LadettoJ G Gribben
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
May 10, 2003·Blood·Paolo CorradiniUNKNOWN Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome
Oct 11, 2005·Mayo Clinic Proceedings·S Vincent Rajkumar, Robert A Kyle
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
May 9, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele CavoMichele Baccarani
Nov 2, 2007·Leukemia·K C AndersonUNKNOWN ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma
Jan 2, 2008·Haematologica·Suryasarathi DasguptaSebastien Lacroix-Desmazes
Aug 2, 2008·Blood·Bruno PaivaUNKNOWN GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Grou
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Juan José LahuertaJesús F San Miguel
Nov 14, 2008·Leukemia·A Palumbo, S V Rajkumar
Jul 28, 2009·Bone Marrow Transplantation·M WangR Alexanian
Jul 30, 2009·Blood·Jean-Luc HarousseauHerve Avet-Loiseau
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Luc HarousseauPhilippe Moreau
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria-Victoria MateosJesús F San Miguel

❮ Previous
Next ❯

Citations

Jul 16, 2013·Leukemia Research·Li BaoXiaojun Huang
May 10, 2003·International Journal of Radiation Oncology, Biology, Physics·Daniela Schulz-ErtnerJürgen Debus
Nov 9, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A RomanoF Di Raimondo
Apr 6, 2013·Immunotherapy·Alessandra RomanoFrancesco Di Raimondo
Sep 6, 2014·British Medical Bulletin·Rebecca E WalkerAndrew D Chantry
Sep 29, 2011·Expert Opinion on Pharmacotherapy·Michel Delforge
Jun 15, 2011·Expert Review of Hematology·Hang QuachAndrew Spencer
Oct 19, 2013·Seminars in Oncology·Cara RosenbaumAndrzej J Jakubowiak
Jul 28, 2015·American Journal of Hematology·Wilson I GonsalvesLuciano J Costa
May 23, 2012·Cancer Treatment Reviews·Meletios A DimopoulosRuben Niesvizky
Sep 12, 2014·Computational and Structural Biotechnology Journal·Ivan Spicka
Dec 30, 2014·Lancet·Christoph RölligMartin Bornhäuser
Dec 16, 2010·Clinical Lymphoma, Myeloma & Leukemia·Jean-Luc Harousseau
Dec 27, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Firoozeh SahebiStephen J Forman
Jul 28, 2011·Blood·S Vincent RajkumarP Leif Bergsagel
Nov 13, 2010·Blood·Andrew Spencer
Jan 24, 2013·Journal of Korean Medical Science·Ho Sup LeeUNKNOWN Korean Multiple Myeloma Working Party (KMMWP)
Jul 10, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ehsan MalekPaolo Caimi
Dec 8, 2015·Hematology·Sagar Lonial, Ajay K Nooka
Nov 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Prashant KapoorMorie A Gertz
Mar 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruno PaivaJesus F San Miguel
Jul 4, 2017·European Journal of Cancer Care·V InnaoC Musolino

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.